Lumvoa received FDA approval as the first treatment for both active and chronic TED, showing rapid and durable efficacy in pivotal trials. Launch strategies target rapid uptake in a large, underpenetrated market, with robust patient support and payer engagement.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.